SlideNewsroom Press Releases In the News Media Inquiries Videos Press Releases Exciting things are happening at Aulos™ Bioscience. Here is the latest news about our company and pipeline. October 13, 2026 Aulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026 ... October 2, 2026 Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual Meeting ... May 21, 2026 Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting ... April 21, 2026 Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting ... November 7, 2025 New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer ... October 3, 2025 Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting ... April 29, 2025 Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting ... April 14, 2025 Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma ... March 25, 2025 Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting ... November 27, 2024 Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer ... 12…5Next
